论文部分内容阅读
目的:对曼月乐治疗子宫腺肌病导致的月经量增多及中度、重度痛经的临床疗效进行探讨。方法:选取2013年6月至2015年5月期间在我院就诊的子宫腺肌病患者40例,随机均分为两组,观察组和对照组,各20例,其中对照组采用口服散结镇痛胶囊治疗,观察组采用宫腔放置曼月乐治疗。对比两组的止痛效果、月经量以及子宫体积变化指标同时观察其不良反应。结果:观察组患者在放置曼月乐分别治疗5个月和11个月之后月经量减少,痛经得到明显缓解,患者子宫腺肌病月经量PBAC评分与痛经VAS评分比对照组的的下降幅度明显(P<0.01),差异有统计学意义,子宫体积和治疗前对比(P>0.05)差异无统计学意义,两组都无明显的不良反应。结论:宫内放置曼月乐是治疗子宫腺肌病最安全且有效的治疗方法,宫内放置曼月乐是一种值得推广的临床治疗方法。
Objective: To investigate the effect of Mirena on the increase of menstrual flow caused by adenomyosis and the clinical effect of moderate and severe dysmenorrhea. Methods: Forty patients with adenomyosis who were treated in our hospital from June 2013 to May 2015 were randomly divided into two groups: observation group (20 cases) and control group (20 cases). The control group was treated with oral Sanjie Analgesic capsule treatment, the observation group using the uterine cavity placed Mirena treatment. The analgesic effect, menstrual volume and uterine volume changes were compared between the two groups to observe the adverse reactions. Results: Menstrual flow decreased and dysmenorrhea was relieved in the observation group after 5 months and 11 months of treatment respectively. The decline rate of menstrual volume PBAC score and dysmenorrhea VAS score in patients with adenomyosis was significantly lower than that in the control group (P <0.01). The difference was statistically significant. There was no significant difference in the uterine volume between the two groups before and after treatment (P> 0.05). There was no obvious adverse reactions in both groups. Conclusion: Intrauterine Mirenais is the safest and effective treatment for adenomyosis. Intrauterine placement of Mirena is a worthy method of clinical treatment.